Aortic stenosis
Conditions
Interventions
Short-term anticoagulation group:Patients will receive anticoagulation therapy with rivaroxaban during the first month post-TAVR, with the specific dosage determined by the investigator based on the p
Standard single antiplatelet group:Patients will receive single antiplatelet therapy with aspirin 100 mg qd or clopidogrel 75 mg qd during the first month post-TAVR. Subsequent antithrombotic strategy
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years; 2. Symptomatic severe aortic valve stenosis successfully treated with TAVR; 3. The participant is able to understand the purpose of the trial, voluntarily agrees to participate, and provides written informed consent reviewed and approved by an ethics committee.
Exclusion criteria
Exclusion criteria: 1. Indications for long-term oral anticoagulant therapy (e.g., pulmonary embolism, deep vein thrombosis, atrial fibrillation etc.); 2. Indications for dual oral antiplatelet therapy (e.g., myocardial infarction, post-coronary revascularization etc.); 3. History of stroke; 4. Intolerance or allergy to rivaroxaban; 5. Presence of a condition at the time of enrollment that is expected to result in a life expectancy of less than 12 months; 6. Inability to complete the study or comply with the study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hierarchical composite of cardiovascular death, first occurrence of myocardial infarction or stroke, first occurrence of life-threatening/disabling/major bleeding, >=50% reduced leaflet motion (RLM), and grade 3 or higher hypo-attenuated leaflet thickening (HALT); | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause Mortality;Cardiovascular Death;Myocardial Infarction;Stroke;Life-threatening or disabling bleeding;Major bleeding;Minor bleeding ;All bleeding;Grade 3 or higher Hypo-attenuated leaflet thickening (HALT);>=50% Reduced leaflet motion (RLM);Kansas City Cardiomyopathy Questionnaire score (KCCQ); | — |
Countries
China
Contacts
Public ContactGuangyuan Song
Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed